Soumya Paul

Soumya Paul is CEO at Pentavalent Biosciences.

Articles

strigana/Stock.Adobe.com – image of magnifying class taking a close look at vials and syringes.

Platform-Specific Risk Assessment of SARS-CoV-2 Vaccines Using FMEA

Rajika Jindani ;Smritie Sheth;Soumya Paul;Anurag S. Rathore;Narendra Chirmule

February 2nd 2021

Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: December 9th 2024 | Updated: December 21st 2024

Recap Key Industry Trends for Viral Clearance and NGS

Published: December 7th 2024 | Updated: December 21st 2024

Enhancing Quality Through Training

Published: July 20th 2020 | Updated: December 21st 2024

Contact BioPharm International Editors

Published: July 19th 2020 | Updated: December 21st 2024

Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777